Abstract: A method of treating obstructive sleep apnea according to this disclosure may include: providing an implant comprising a substantially planar central body portion having a top side and a bottom side; at least two adjustable wing portions; and at least two connecting members, each one of the at least two connecting members extending from opposite sides of the central body portion, the each one of the at least two connecting members being configured for flexibly connecting each one of the at least two wing portions at opposite sides to said central body portion; forming a surgical opening to expose a genioglossus muscle; exposing a branch of a hypoglossal nerve for stimulation by the implant at least on one side of the geniouglossus; forming at least one pocket on at least one side of the geniouglossus; such that the pocket dimensions are configured to fit the at least one of the at least two wing portions of the device; inserting an implant device through the surgical opening such that the central body extends

Abstract: The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell.

Abstract: The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell.

Abstract: A bioreactor (100) for a vascularized structure (200) is provided comprising a vasculated portion (202) and a vascular pedicle (204), the bioreactor (100) comprising a first void space (112) configured to receive the vascular pedicle (204) optionally contained in a first vessel (110) having a first opening (114), a second void space (142) in fluid contact with at least part of the vasculated portion (202), and a support element (170) for supporting the vascularized structure (200) and fluidly separating the first void space (112) from the second void space (142), comprising an aperture region (176) comprising one or more apertures configured to receive at least part of the vascular pedicle (204).

Abstract: The present invention relates to an isolated transgenic pig beta cell wherein the PKC and the PKA pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention. The present invention also relates to the use of said transgenic pig beta cell, said transgenic pig islet, or said device for treating a disease, disorder or condition related to the impaired function of endocrine pancreas or of beta cell.

Abstract: The present invention relates to a modified pig islet capable of producing higher levels of glucagon than a native pig islet or capable of producing a glucagon analog, and methods for obtaining thereof. The invention also relates to a method for treating Diabetes Mellitus, and/or for regulating blood glucose levels in a subject in need thereof, comprising the administration of the modified pig islets of the invention.

Abstract: The present invention is directed to cellular devices comprising a collagen matrix, cell layer, and gelled alginate layer, processes for producing the devices, methods of implanting the devices, and methods of treatment thereof.

Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.

Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.

Abstract: A monoclonal antibody which binds to baboon and human CD2, and in particular LO-CD2b antibody. The antibody may be employed to prevent and inhibit an immune response in human patients, such as when the immune response is mediated by the activation and proliferation of T-cells or natural killer cells.